Rahul Somvanshi
If a rapid antigen test told you “negative” while you felt sick, a new FDA-cleared molecular test offers another option. It is intended for people who want a non-prescription test that detects SARS-CoV-2 from a clinical specimen.
The FDA cleared Aptitude Medical Systems Metrix COVID Test and Metrix COVID Test Pro through the traditional 510(k) pathway. The FDA database lists the devices as over-the-counter molecular tests for detecting SARS-CoV-2 from clinical specimens. The decision date was August 7, 2026. Aptitude announced the clearance on September 16. The test uses either an anterior nasal swab or saliva sample and produces a result in about 30 minutes. Aptitude says the next-generation version has approximately three-fold higher analytical sensitivity and results that are 30% faster than the original EUA-authorized Metrix product.
For people who need a molecular result at home, the clearance creates a non-prescription testing option. A positive result may help a patient contact a clinician quickly about treatment. Paxlovid, when prescribed, must be started within five days of symptom onset. The Metrix clearance itself does not diagnose a patient’s need for treatment, and the test does not replace medical advice.
How Molecular Detection Differs From Antigen Tests
Rapid antigen tests detect viral proteins. Molecular tests detect genetic material from the virus. The FDA-cleared Metrix devices use the Metrix molecular platform and are intended to detect SARS-CoV-2 in clinical specimens. The FDA clearance record establishes the device’s regulatory status, but it does not establish that the test detects infection during an incubation period or that it is three times more sensitive than every at-home antigen test.
Aptitude’s announcement compares the new product with the original EUA-authorized Metrix product. It does not support a general comparison with all antigen tests. The company has also described a COVID/flu product in development, but this article does not treat that product as cleared by the FDA.
How accurate is the Metrix molecular test compared with a lab PCR? The FDA clearance confirms that the Metrix COVID Test and Metrix COVID Test Pro are molecular tests cleared through the 510(k) pathway. The available clearance record does not support a claim that they are identical to every laboratory PCR test. Users should follow the product instructions and seek clinical advice when symptoms persist or treatment may be needed.
The FDA says COVID-19 medical-device EUA declarations are scheduled to terminate on December 26, 2026. The agency’s transition guidance says EUAs listed on its website will no longer be in effect on that date. The traditional clearance gives Aptitude a separate regulatory route for the cleared devices.
For more on FDA regulatory approvals, see FDA Approves Inluriyo for ESR1-Mutated Breast Cancer and US Microplastics Stomp CCL6 Research.
